COUNTRY HISTORY

 

Merck Sharp & Dohme (MSD Egypt) have been established in Egypt as a Scientific Office since 1960. From 1960 until 1984, MSD products have either been imported through a public sector distribution company (EGYDRUG), or locally manufactured through a government owned manufacturer (Al-Kahira Company) and a private sector company (EIPICO).

Throughout these years, (MSD Egypt) introduced to Egyptian patients milestone treatments for various diseases:

1. Methyldopa, the 1st centrally acting anti-hypertensive.

2. Indomethacin, a breakthrough in arthritis treatment that became the standard to which other molecules compares to.

3. The 60's also witnessed the introduction of the diuretic Hydroclorothiazide;, a centrally acting tricyclic antidepressant (Amitriptyline), and a new treatment for parkinsonism (Carbidopa/Levodopa).

4. In the 80's, Timolol, the 1st topical beta-blocker eye drops used for glaucoma treatment, and Norfloxacin, a quinolone used for urinary tract infections.

Between the years 1994 and 2001, registration and new product introductions were the primary objectives of our organization. (MSD Egypt) was able to introduce in the Egyptian market the following new breakthrough products:

1. Finasteride, the first 5- alpha reductase inhibitor,that causes regression of (BPH).

2. Imipenem, the 1st thienamycin antibiotic for treatment of life threatening infections.

3. Simvastatin, a (HMG-CoA) reductase inhibitor proven to reduce mortality in (CHD) patients with hypercholesterolemia.

4. Enalapril, a long acting (ACE) inhibitor for the treatment of hypertension and heart failure.

5. Losartan, an (A2) antagonist for the treatment of hypertension.

6. Alendronate, the 1st non-hormonal therapy for osteoporosis with proven fracture reduction.

7. Rofecoxib, the 1st Cox-2 inhibitor available in Egypt for treatment of osteo-arthritis, pain, and primary dysmenorrhea.

8. Dorzolamide, the 1st topical carbonic anhydrase inhibitor, a long awaited breakthrough in glaucoma therapy

9. Montelukast, the 1st leukotriene receptor antagonist for treatment of asthma.

As of January 1st 2000, Global Napi Pharmaceuticals (GNP) became Merck & Co., Inc., licensee in Egypt. RAMCO, SOFICO PHARM and EGYDRUG are the distributors of MSD products in Egypt.

Worldwide, Merck & Co., Inc. markets medicines in 20 therapeutic categories - the broadest product line in the pharmaceutical industry. Overall, Merck & Co., Inc. markets more than 100 medicines and vaccines throughout the world.